Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and …

Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …

Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …

Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …

Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …

The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …

Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

BACKGROUND This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed the
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …

Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …

The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …